What Is Driving the Shift in Ironwood Pharmaceuticals' Fair Value Story? Ironwood Pharmaceuticals has seen its analyst fair value estimate move from about US$2.50 to roughly US$4.85 per share, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results